https://www.ncbi.nlm.nih.gov/pubmed/25830296
Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
CONCLUSIONS AND RELEVANCE:
Available toxicity information from clinical trials of finasteride in men with AGA is very limited, is of poor quality, and seems to be systematically biased. In a cohort of men prescribed finasteride for routine treatment of AGA, most would have been excluded from the pivotal studies that supported US Food and Drug Administration approval for AGA. Published reports of clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of AGA.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064044/
a substantial body of evidence exists
which points to serious and potentially ill-health effects of 5?-RIs' therapy. These include loss or reduced libido, erectile dysfunction, orgasmic and ejaculatory dysfunction (Table 2) [99], development of high grade PCa tumors (Fig. 4), potential negative cardiovascular events, and depression. The side effects are potentially harmful in some individuals and in young men may be persistent or irreversible [100]. The argument that the benefits of these drugs outweighs the risks is slowly eroding in the face of new emerging scientific evidence from preclinical (Figs. 2, ?,3;3; Table 1) and clinical studies (Table 2). The available data demonstrate that such drugs do pose serious adverse effects, especially in a subset of men who may have the predisposition to be affected severely. This is also corroborated by the overwhelming FDA disapproval of these drugs for the chemoprevention of PCa. The FDA mandated relabeling issued in 2011 equally points to the dark side of these drugs on human health.
@Hopsaflopsa: Ja ik zal zeker die andere thread binnekort updaten. Dit is ook belangrijk vind ik.